BidaskClub lowered shares of Insulet (NASDAQ:PODD) from a strong-buy rating to a buy rating in a research note issued to investors on Tuesday.

Several other equities research analysts also recently commented on PODD. BMO Capital Markets boosted their target price on shares of Insulet to $115.00 and gave the company a top pick rating in a research note on Tuesday, July 10th. Oppenheimer set a $96.00 target price on shares of Insulet and gave the company a hold rating in a research note on Friday, August 3rd. Piper Jaffray Companies boosted their target price on shares of Insulet to $106.00 and gave the company an overweight rating in a research note on Monday, June 4th. Leerink Swann restated an outperform rating and issued a $130.00 target price on shares of Insulet in a research note on Tuesday, September 11th. Finally, Zacks Investment Research upgraded shares of Insulet from a hold rating to a buy rating and set a $96.00 target price on the stock in a research note on Tuesday, August 7th. Four equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. Insulet currently has a consensus rating of Buy and a consensus target price of $95.24.

Shares of NASDAQ:PODD opened at $105.34 on Tuesday. Insulet has a 52 week low of $54.55 and a 52 week high of $108.90. The company has a current ratio of 5.54, a quick ratio of 5.01 and a debt-to-equity ratio of 3.22.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, August 2nd. The medical instruments supplier reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. Insulet had a negative net margin of 3.47% and a negative return on equity of 11.91%. The company had revenue of $124.26 million for the quarter, compared to the consensus estimate of $132.89 million. During the same quarter in the previous year, the company earned ($0.13) EPS. The firm’s revenue for the quarter was up 13.2% compared to the same quarter last year. sell-side analysts predict that Insulet will post -0.09 earnings per share for the current year.

In related news, EVP Aiman Abdel-Malek sold 602 shares of the company’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $86.60, for a total transaction of $52,133.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Michael P. Spears sold 5,043 shares of the company’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $86.08, for a total transaction of $434,101.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 7,207 shares of company stock worth $651,334. 3.60% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Pier 88 Investment Partners LLC acquired a new position in Insulet during the 2nd quarter worth about $184,000. First Republic Investment Management Inc. acquired a new position in Insulet during the 1st quarter worth about $209,000. Brinker Capital Inc. acquired a new position in Insulet during the 1st quarter worth about $249,000. Harbour Capital Advisors LLC acquired a new position in Insulet during the 2nd quarter worth about $269,000. Finally, LPL Financial LLC acquired a new position in Insulet during the 1st quarter worth about $276,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Read More: How Do I Invest in Dividend Stocks

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.